$HCTI
Healthcare Triangle, Inc. Stock $hcti

$hcti Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000160706223000398 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$7.779M	$8.526M
YoY Change	-34.9%	-26.42%
Cost Of Revenue	$6.072M	$6.579M
YoY Change	-28.75%	-21.95%
Gross Profit	$1.707M	$1.947M
YoY Change	-50.2%	-38.37%
Gross Profit Margin	21.94%	22.84%
Selling, General & Admin	$2.470M	$2.638M
YoY Change	-25.04%	-14.96%
% of Gross Profit	144.7%	135.49%
Research & Development	$54.00K	$102.0K
YoY Change	-96.33%	-84.21%
% of Gross Profit	3.16%	5.24%
Depreciation & Amortization	$710.0K	$802.0K
YoY Change	-21.89%	-4.98%
% of Gross Profit	41.59%	41.19%
Operating Expenses	$3.231M	$3.542M
YoY Change	-43.07%	-22.87%
Operating Profit	-$1.524M	-$1.595M
YoY Change	-32.18%	11.3%
Interest Expense	-$420.0K	-$186.0K
YoY Change	663.64%	-420.69%
% of Operating Profit
Other Income/Expense, Net		$0.00
YoY Change		-100.0%
Pretax Income	-$1.939M	-$1.781M
YoY Change	-15.77%	340.84%
Income Tax	$4.000K	$5.000K
% Of Pretax Income
Net Earnings	-$1.943M	-$1.786M
YoY Change	-16.93%	340.99%
Net Earnings / Revenue	-24.98%	-20.95%
Basic Earnings Per Share	-$0.45	-$0.42
Diluted Earnings Per Share	-$0.46	-$0.42
COMMON SHARES
Basic Shares Outstanding	4.278M shares	42.78M shares
Diluted Shares Outstanding	4.278M shares	4.273M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$80.00K	$132.0K
YoY Change	-98.07%	-90.32%
Cash & Equivalents	$75.00K	$132.0K
Short-Term Investments
Other Short-Term Assets	$622.0K	$816.0K
YoY Change	166.95%	22.16%
Inventory
Prepaid Expenses
Receivables	$4.000K	$4.476M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$4.893M	$5.424M
YoY Change	-55.84%	-36.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.00K	$57.00K
YoY Change	-35.53%	-29.63%
Goodwill	$1.289M	$1.289M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		-$1.000M
YoY Change
Total Long-Term Assets	$9.573M	$10.64M
YoY Change	-30.55%	-22.93%
TOTAL ASSETS
Total Short-Term Assets	$4.893M	$5.424M
Total Long-Term Assets	$9.573M	$10.64M
Total Assets	$14.47M	$16.07M
YoY Change	-41.82%	-28.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.161M	$926.0K
YoY Change	-20.91%	-27.09%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.479M	$3.531M
YoY Change	41.83%	9.93%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.852M	$5.790M
YoY Change	35.42%	-4.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.490M	$2.227M
YoY Change	-33.09%	0.0%
Total Long-Term Liabilities	$1.490M	$2.227M
YoY Change	-33.09%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.852M	$5.790M
Total Long-Term Liabilities	$1.490M	$2.227M
Total Liabilities	$8.339M	$8.017M
YoY Change	14.44%	-3.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.58M	-$17.63M
YoY Change	163.86%	247.09%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.127M	$8.051M
YoY Change
Total Liabilities & Shareholders Equity	$14.47M	$16.07M
YoY Change	-41.82%	-28.23%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.943M	-$1.786M
YoY Change	-16.93%	340.99%
Depreciation, Depletion And Amortization	$710.0K	$802.0K
YoY Change	-21.89%	-4.98%
Cash From Operating Activities	$0.00	-$1.221M
YoY Change	-100.0%	-507.0%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$0.00
YoY Change	-100.78%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	$0.00
YoY Change	-99.22%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	1.086M
YoY Change	-100.99%	-27.74%
NET CHANGE
Cash From Operating Activities	0.000	-1.221M
Cash From Investing Activities	-10.00K	0.000
Cash From Financing Activities	-50.00K	1.086M
Net Change In Cash	-60.00K	-135.0K
YoY Change	-102.16%	-32.16%
FREE CASH FLOW
Cash From Operating Activities	$0.00	-$1.221M
Capital Expenditures	$10.00K	$0.00
Free Cash Flow	-$10.00K	-$1.221M
YoY Change	-103.24%	-153.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001839285
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Other Income OtherIncome		usd
	HCTI	Income From Ppp IncomeFromPpp		usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments		usd
	HCTI	Increase Decrease In Intangible Assets IncreaseDecreaseInIntangibleAssets		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
CY2023Q2	us-gaap	Other Noncash Income OtherNoncashIncome		usd
CY2023Q2	HCTI	Business Combination Working Capital BusinessCombinationWorkingCapital		usd
CY2023Q2	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness		usd
CY2023Q2	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2022Q4	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40903
	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE TRIANGLE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3559776
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7901 Stoneridge Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
	dei	City Area Code CityAreaCode	(925)
	dei	Local Phone Number LocalPhoneNumber	270-4812
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	HCTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4277863	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1341000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4476000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5592000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	816000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	816000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5424000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7749000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8921000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	1289000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1289000	usd
CY2023Q2	HCTI	Dues From Affiliates DuesFromAffiliates	1377000	usd
CY2022Q4	HCTI	Dues From Affiliates DuesFromAffiliates	1075000	usd
CY2023Q2	us-gaap	Assets Assets	16068000	usd
CY2022Q4	us-gaap	Assets Assets	20763000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	926000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000	usd
CY2023Q2	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2022Q4	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	3531000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	2412000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1278000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2200000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5790000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6148000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	8017000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8375000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	HCTI	Preferred Stock Voting Shares PreferredStockVotingShares	6000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4277863	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4170953	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25683000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24956000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17632000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12568000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8051000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16068000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20763000	usd
CY2023Q2	us-gaap	Revenues Revenues	8526000	usd
CY2022Q2	us-gaap	Revenues Revenues	11588000	usd
	us-gaap	Revenues Revenues	18364000	usd
	us-gaap	Revenues Revenues	22644000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	6579000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	8429000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	14824000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	16591000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	646000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	641000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1712000	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1026000	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1651000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2787000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3391000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1612000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1451000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3240000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2802000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	802000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	844000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1676000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1555000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3542000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4592000	usd
	us-gaap	Operating Expenses OperatingExpenses	8344000	usd
	us-gaap	Operating Expenses OperatingExpenses	9460000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1595000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1433000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4804000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3407000	usd
CY2022Q2	us-gaap	Other Income OtherIncome	1087000	usd
	us-gaap	Other Income OtherIncome	12000	usd
	us-gaap	Other Income OtherIncome	1087000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-186000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-58000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-248000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-74000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1781000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-404000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5040000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2394000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1786000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-405000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5064000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2416000	usd
CY2023Q2	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.42
CY2022Q2	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.11
	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-1.20
	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.68
CY2023Q2	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	4228379	shares
CY2022Q2	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3548429	shares
	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	4228379	shares
	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3548429	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9303000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1786000	usd
CY2023Q2	HCTI	Preferential Issue PreferentialIssue	499000	usd
CY2023Q2	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	35000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8051000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	177000	usd
	HCTI	Preferential Issue PreferentialIssue	499000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51000	usd
	us-gaap	Profit Loss ProfitLoss	-5064000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8051000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14499000	usd
CY2022Q2	HCTI	Stock Compensation Expenses StockCompensationExpenses	12000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-405000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16135000	usd
	HCTI	Stock Compensation Expenses StockCompensationExpenses	27000	usd
	HCTI	Cash Collected On Common Stock Options Shares CashCollectedOnCommonStockOptionsShares	2614000	shares
	HCTI	Cash Collected On Common Stock Options CashCollectedOnCommonStockOptions	10000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	350000	usd
	us-gaap	Profit Loss ProfitLoss	-2416000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5064000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2416000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1676000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1555000	usd
	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	51000	usd
	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	350000	usd
	HCTI	Income From Ppp IncomeFromPpp	-1068000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	174000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1116000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3125000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	306000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-698000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	534000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-555000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-603000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-922000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	564000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	97000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2826000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	602000	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2000	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	22000	usd
	HCTI	Increase Decrease In Intangible Assets IncreaseDecreaseInIntangibleAssets	-2000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2022000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1119000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1003000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1619000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1013000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1209000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-407000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1341000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1770000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1363000	usd
	us-gaap	Interest Expense InterestExpense	248000	usd
	us-gaap	Interest Expense InterestExpense	74000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	24000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	22000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zqUoW3NNExE8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_86C_zZfUNK8pNKnc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the standalone selling price for each distinct performance obligation</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the determination of the period of benefit for amortization of deferred costs.</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the fair value of assets acquired, and liabilities assumed for business combinations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation including warrants</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8526000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11588000	usd
CY2023Q2	HCTI	Changes Amount ChangesAmount	-3062000	usd
CY2023Q2	HCTI	Changes Percentage ChangesPercentage	-0.26	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18364000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	22644000	usd
	HCTI	Changes Amount ChangesAmount	-4280000	usd
	HCTI	Changes Percentage ChangesPercentage	-0.19	pure
CY2023Q2	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	-263000	usd
CY2022Q2	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	751000	usd
CY2023Q2	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-488000	usd
CY2023Q2	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-0.65	pure
CY2023Q2	HCTI	Unallocated Costs UnallocatedCosts	1858000	usd
CY2022Q2	HCTI	Unallocated Costs UnallocatedCosts	2184000	usd
CY2023Q2	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	-326000	usd
CY2023Q2	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0.15	pure
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1595000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1433000	usd
CY2023Q2	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	-162000	usd
CY2023Q2	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	-0.11	pure
CY2022Q2	us-gaap	Other Noncash Income OtherNoncashIncome	1087000	usd
CY2023Q2	HCTI	Other Income Amount Changes OtherIncomeAmountChanges	-1087000	usd
CY2023Q2	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	-1	pure
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	186000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	58000	usd
CY2023Q2	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-128000	usd
CY2023Q2	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	-2.21	pure
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1781000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-404000	usd
CY2023Q2	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	-1377000	usd
CY2023Q2	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	-3.41	pure
	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	-784000	usd
	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	1233000	usd
	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-2017000	usd
	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-1.64	pure
	HCTI	Unallocated Costs UnallocatedCosts	4020000	usd
	HCTI	Unallocated Costs UnallocatedCosts	4640000	usd
	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	-620000	usd
	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0.13	pure
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4804000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3407000	usd
	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	-1397000	usd
	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	-0.41	pure
	us-gaap	Other Noncash Income OtherNoncashIncome	12000	usd
	us-gaap	Other Noncash Income OtherNoncashIncome	1087000	usd
	HCTI	Other Income Amount Changes OtherIncomeAmountChanges	-1075000	usd
	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	-0.99	pure
	us-gaap	Interest Expense Debt InterestExpenseDebt	248000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	74000	usd
	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-174000	usd
	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	-2.35	pure
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5040000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2394000	usd
	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	-2646000	usd
	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	-1.11	pure
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	4476000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5592000	usd
CY2023Q2	HCTI	Warrant Liabilities WarrantLiabilities	55000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2227000	usd
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_z910UOUjIZC3" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_86E_zkuyEKOxTUZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the quarter ended June 30, 2023 and 2022 revenue from the top five customers accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230101__20230630__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1vjqp3dnzs3">81</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20220630__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_znBD82BEFYgl">73</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total revenue respectively. For the quarter ended June 30, 2023 and year ended December 31, 2022 accounts receivable from five major customers accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230101__20230630__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zIgtX2FHPM41">81</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20220630__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFONabqxFEde">72</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the total accounts receivables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20230630_z7qvRK01jqB7">250,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(valid through June 30, 2023) per institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023 and December 31, 2022, the Company had Nil<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_c20230630_z0RwojM1pZng" style="color: White">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_c20221231_z3CndSZMdure">816 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</span></p>
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	816000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	123000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	119000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
	us-gaap	Depreciation Depreciation	10000	usd
	us-gaap	Depreciation Depreciation	8500	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7552000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8921000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5903000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	792000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	793000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	1538000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	3077000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	3020000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	1286000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8921000	usd
CY2023Q2	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	756000	usd
CY2022Q2	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	218000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	67000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	43000	usd
CY2023Q2	HCTI	Due From Related Party DueFromRelatedParty	9000	usd
CY2022Q2	HCTI	Due From Related Party DueFromRelatedParty	0	usd
	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	4500000	usd
	HCTI	Weighted Average Price Of Stock Amount WeightedAveragePriceOfStockAmount	700000	usd
	HCTI	Unvested Common Stock UnvestedCommonStock	8372	shares
	HCTI	Earnout Payment EarnoutPayment	2500000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2209000	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-04-30
CY2023Q2	us-gaap	Goodwill Gross GoodwillGross	1289000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	6018000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1289000	usd
CY2023Q2	us-gaap	Cash Cash	970000	usd
CY2023Q2	HCTI	Business Combination Acquisition Accounts Receivables BusinessCombinationAcquisitionAccountsReceivables	3142000	usd
CY2023Q2	HCTI	Business Combination Acquisition Other Assets Current BusinessCombinationAcquisitionOtherAssetsCurrent	11419000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	758000	usd
CY2023Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	2209000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	679000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3646000	usd
CY2023Q2	HCTI	Net Working Capital Acquired NetWorkingCapitalAcquired	7773000	usd
CY2023Q2	HCTI	Total Business Acquisitions Purchase Price TotalBusinessAcquisitionsPurchasePrice	7773000	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	28.8
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	55000	usd
	HCTI	Estimated Fair Value Of Common Stock Warrant EstimatedFairValueOfCommonStockWarrant	4.0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	28.8
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.01	pure
CY2023Q2	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2352000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3212000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1179	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1361000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2578000	usd
CY2023Q2	HCTI	Stockbased Compensation StockbasedCompensation	-47000	usd
CY2022Q4	HCTI	Stockbased Compensation StockbasedCompensation	-27000	usd
CY2022Q4	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness	292000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1314000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2843000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1314000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2843000	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	usd
	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	5000	usd
	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	1000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	208514	shares
CY2023Q1	HCTI	Incentive Stock Options Iso IncentiveStockOptionsIso	200000	shares
CY2023Q1	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	880757	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	12386	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	332824	shares
CY2023Q2	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	11226	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	70000000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	274050	shares
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	309000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1786000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-405000	usd
	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	4228379	shares
	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	3548429	shares
	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.42	shares
	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.11	shares

Files In Submission

Name	View Source	Status
0001607062-23-000398-index-headers.html	Edgar Link	pending
0001607062-23-000398-index.html	Edgar Link	pending
0001607062-23-000398.txt	Edgar Link	pending
0001607062-23-000398-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcti-20230630.xsd	Edgar Link	pending
hcti063023form10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hcti-20230630_cal.xml	Edgar Link	unprocessable
hcti-20230630_def.xml	Edgar Link	unprocessable
hcti-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hcti-20230630_lab.xml	Edgar Link	unprocessable
hcti063023form10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCTI
Healthcare Triangle, Inc. Stock $hcti

2023 Q3 Form 10-Q Financial Statement

#000160706223000398 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI Healthcare Triangle, Inc. Stock $hcti

2023 Q3 Form 10-Q Financial Statement

#000160706223000398 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI
Healthcare Triangle, Inc. Stock $hcti